Cancer R&D has never been more promising. Yet pricing and access to this new world of cancer therapy remains thorny. These issues have to be resolved if society is going to reap the benefits of this work. Come hear from some of the leading scientists, entrepreneurs, and investors about how they are thinking about the future. All ticket proceeds go to support cancer research at Fred Hutch.

AGENDA

1:00 p.m. | Registration

1:30 p.m. | Welcome

• Lesley Stolz, head, JLABS Bay Area
• Luke Timmerman

1:35 p.m. | Why I’m Doing Kilimanjaro Climb to Fight Cancer (60 seconds each)

• Lesley Stolz, head, JLABS Bay Area
• Bill Newell, CEO, Sutro Biopharma
• Ken Brunt, VP of customer operations, Veracyte
• Julia Owens, CEO, Millendo Therapeutics

1:40 p.m. | Why Genentech is Betting Big on Personalized T-cell therapies

• Ira Mellman, vice president, research oncology, Genentech
• Harlan Robins, member, Fred Hutch; program head, computational biology; co-founder, Adaptive Biotechnologies
• Kristina Burow, managing director, ARCH Venture Partners (moderator)

2:00 p.m. | New Ideas for Cancer Treatment (10 minutes each)

• Carolyn Bertozzi, Anne T. and Robert M. Bass Professor of Chemistry at Stanford; Co-Founder, Palleon Pharmaceuticals (targeting glycan sensing checkpoints)
• Omid Farokhzad, CEO, Seer (proteomics for early cancer detection)
• Angie You, CEO, Amunix Pharmaceuticals (protein therapeutics)
• Steve James, CEO, Pionyr Immunotherapeutics (antibodies for immune responses in tumor microenvironment)
• Daniel Corey, founder and CSO, Cero Therapeutics (engineered cells to engulf and degrade tumors)
• Alex Franzusoff, CEO, PACT Pharma
• Ben Hindson, co-founder and CSO, 10X Genomics (insights from single-cell analysis)

3:10 p.m. | The Future of Cancer Immunotherapy. T-cells, bispecifics, all of the above?

• David Chang, co-founder and CEO, Allogene Therapeutics
• Bassil Dahiyat, CEO, Xencor
• Stanley Riddell, member, Fred Hutch; scientific director, Immunotherapy Integrated Research Center; co-founder, Juno Therapeutics
• Julia Owens, CEO, Millendo Therapeutics (moderator)

3:30 p.m. | BREAK

3:50 p.m. | Beyond the Science: Regulatory, Commercial and Data Transformations Enabling the Cancer Revolution

• Amy DuRoss, CEO, Vineti
• Kristen Hege, Corporate VP, translational development, hematology/oncology, Celgene
• Ashley Koegel, postdoctoral fellow, Wendell Lim laboratory, UCSF
• Tim Moore, EVP, technical operations, Kite Pharma
• Nina Kjellson, general partner, Canaan Partners (moderator)

4:30 p.m. | What Will it Take for Molecular Diagnostics Reach Their Potential?

• Bonnie Anderson, co-founder and CEO, Veracyte
• Kevin Conroy, CEO, Exact Sciences
• Lesley Stolz, JLABS Bay Area (moderator)

5:00 p.m. | Closing Conversation on the Future for Cancer Care

• Hal Barron, chief scientific officer and president of R&D, GSK
• Larry Corey, past president of Fred Hutch, co-PI, HIV Vaccine Trials Network; co-founder, Juno Therapeutics
• Racquel Bracken, vice president, Venrock (moderator)

5:30 p.m. | A Word on the Kilimanjaro Climb to Fight Cancer.

• Luke Timmerman

5:35 p.m. | NETWORKING

6:00 p.m. | END

Sponsors:

• Veracyte
• Nektar Therapeutics
• Alexandria Real Estate Equities 
• Takeda Pharmaceuticals
• Foundation Medicine
• Madryn Asset Management
• Servier
• Sofinnova
• ATUM Bio
• 5AM Ventures
• Pfizer
• Blueprint Medicines
• Zymeworks
• Johnson & Johnson Innovation, JLABS
• Biocom